Cannara Biotech Inc Total Assets
Cannara Biotech Inc total assets. Based on the latest financial reports, Cannara Biotech Inc (LOVE) holds total assets worth CA$173.84 Million CAD (≈ $125.76 Million USD) as of November 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LOVE market cap for the company's overall valuation and market capitalisation.
Total Assets of Cannara Biotech Inc (2018–2025)
Total assets of Cannara Biotech Inc from 2018 to 2025. This chart illustrates how Cannara Biotech Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Cannara Biotech Inc for real-time trading data and today's change.
Cannara Biotech Inc - Asset Composition Analysis
Cannara Biotech Inc Total Assets Breakdown (August 2025)
Cannara Biotech Inc total assets breakdown as of August 2025. Cannara Biotech Inc's total assets of CA$173.84 Million consist of 48.7% current assets and 51.3% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 8.5% |
| Accounts Receivable | CA$14.11 Million | 8.4% |
| Inventory | CA$51.33 Million | 30.4% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Cannara Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore LOVE net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cannara Biotech Inc's current assets represent 48.7% of total assets in 2025, an increase from 46.7% in 2018.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, down from 44.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 30.4% of total assets.
Cannara Biotech Inc Competitors by Total Assets
Key competitors of Cannara Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Cannara Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.70 | 2.01 | 3.39 |
| Quick Ratio | 1.05 | 0.86 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$53.54 Million | CA$36.74 Million | CA$7.42 Million |
Cannara Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Cannara Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | 9.0% |
| Total Assets | CA$168.65 Million |
| Market Capitalization | $126.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cannara Biotech Inc's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cannara Biotech Inc's assets grew by 9.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cannara Biotech Inc (2018–2025)
The table below shows the annual total assets of Cannara Biotech Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | CA$168.65 Million ≈ $122.00 Million |
+9.00% |
| 2024-08-31 | CA$154.72 Million ≈ $111.92 Million |
+9.33% |
| 2023-08-31 | CA$141.52 Million ≈ $102.38 Million |
+12.66% |
| 2022-08-31 | CA$125.62 Million ≈ $90.87 Million |
+36.51% |
| 2021-08-31 | CA$92.02 Million ≈ $66.57 Million |
+67.77% |
| 2020-08-31 | CA$54.85 Million ≈ $39.68 Million |
-19.46% |
| 2019-08-31 | CA$68.10 Million ≈ $49.26 Million |
+135.98% |
| 2018-08-31 | CA$28.86 Million ≈ $20.88 Million |
-- |
About Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. I… Read more